166 related articles for article (PubMed ID: 37925934)
1. Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling.
Ruiz-Mitjana A; Vidal-Sabanés M; Navaridas R; Perramon-Güell A; Yeramian A; Nicholson-Sabaté N; Egea J; Encinas M; Matias-Guiu X; Dolcet X
Biomed Pharmacother; 2023 Dec; 168():115817. PubMed ID: 37925934
[TBL] [Abstract][Full Text] [Related]
2. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Iglesias DA; Yates MS; van der Hoeven D; Rodkey TL; Zhang Q; Co NN; Burzawa J; Chigurupati S; Celestino J; Bowser J; Broaddus R; Hancock JF; Schmandt R; Lu KH
Mol Cancer Ther; 2013 Dec; 12(12):2847-56. PubMed ID: 24077915
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
4. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.
Lange C; Machado Weber A; Schmidt R; Schroeder C; Strowitzki T; Germeyer A
PLoS One; 2021; 16(3):e0248103. PubMed ID: 33690729
[TBL] [Abstract][Full Text] [Related]
5. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
[TBL] [Abstract][Full Text] [Related]
6. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
7. Fluorene-9-bisphenol inhibits epithelial-mesenchymal transition of human endometrial cancer Ishikawa cells by repressing TGF-β signaling pathway.
Wang L; Zhuang T; Li F; Wei W
Environ Sci Pollut Res Int; 2019 Sep; 26(26):27407-27413. PubMed ID: 31327139
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
9. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.
Park S; Willingham MC; Qi J; Cheng SY
Endocr Relat Cancer; 2018 Oct; 25(10):865-877. PubMed ID: 29914872
[TBL] [Abstract][Full Text] [Related]
10. Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Christodoulou MI; Scorilas A
Curr Med Chem; 2017; 24(1):14-56. PubMed ID: 27604091
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells.
Liu Z; Qi S; Zhao X; Li M; Ding S; Lu J; Zhang H
Oncotarget; 2016 Apr; 7(16):21315-31. PubMed ID: 26824324
[TBL] [Abstract][Full Text] [Related]
12. Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation.
Eritja N; Navaridas R; Ruiz-Mitjana A; Vidal-Sabanés M; Egea J; Encinas M; Matias-Guiu X; Dolcet X
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638474
[TBL] [Abstract][Full Text] [Related]
13. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCAA metabolism to potentiate metformin's therapeutic efficacy in the treatment of diabetes in mice.
Zhao X; Zhang X; Pei J; Liu Y; Niu W; Sun H
Diabetologia; 2023 Nov; 66(11):2139-2153. PubMed ID: 37581618
[TBL] [Abstract][Full Text] [Related]
15. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional mechanisms of metformin in cancer treatment.
Singh-Makkar S; Pandav K; Hathaway D; Paul T; Youssef P
Tumori; 2022 Apr; 108(2):111-118. PubMed ID: 34139918
[TBL] [Abstract][Full Text] [Related]
17. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Ikhlas S; Ahmad M
Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
[TBL] [Abstract][Full Text] [Related]
18. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Martin-Castillo B; Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
Cell Cycle; 2010 Mar; 9(6):1057-64. PubMed ID: 20305377
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
[TBL] [Abstract][Full Text] [Related]
20. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.
Cantrell LA; Zhou C; Mendivil A; Malloy KM; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2010 Jan; 116(1):92-8. PubMed ID: 19822355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
